TARSTarsus Pharmaceuticals, Inc.vs its industry peers
A metric-by-metric comparison of Tarsus Pharmaceuticals, Inc. against SIC 2836 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TARSThis | $3.4B#5 | — | 9.8x#5 | 7.5x#1 | 146.7%#1 | 43.1%#3 | -15.7%#1 | -19.0%#2 | -33.0%#2 | — | 53.5%#4 | — |
| IMVT | $7.5B#1 | — | 10.2x#6 | — | — | -22.2%#5 | — | -68.8%#7 | — | — | 138.2%#2 | — |
| CRSP | $5.0B#2 | — | 2.9x#3 | 1438.0x#5 | -90.6%#5 | -58.8%#6 | -18933.6%#5 | -33.3%#4 | -32.6%#1 | — | -14.6%#5 | — |
| ADPT | $4.4B#3 | — | 30.9x#7 | 16.0x#2 | 54.8%#3 | 62.7%#2 | -20.6%#2 | -41.6%#5 | — | — | 114.7%#3 | — |
| RLAY | $4.1B#4 | — | 4.6x#4 | 269.0x#4 | 53.4%#4 | 18.1%#4 | -1971.6%#4 | -31.1%#3 | — | — | 357.0%#1 | — |
| RVMDW | $2.8B#6 | — | 1.1x#1 | — | — | -88.5%#7 | — | -43.4%#6 | — | — | — | — |
| BEAM | $2.4B#7 | — | 2.2x#2 | 17.1x#3 | 120.0%#2 | 78.8%#1 | -274.6%#3 | -7.5%#1 | -40.5%#3 | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-09-16.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice